Madrigal Pharmaceuticals, Inc. (MDGL) Q2 FY26 Earnings Call

Commercial momentum remains strong, with 71% sales growth and management comfortable with consensus growth through 2026 [5][11].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-30
Length62 minutes
EPS$-1.99
EPS consensus$-2.55
Revenue$364.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All MDGL earnings ยท Back to MDGL overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.